New Research Sheds Light on Intentional Non-adherence in Clinical Trials First-of-its-kind study leverages objective adherence data collected by AiCure to illustrate scope of intentional non-adherence Study findings help inform best practices to lower non-adherence...
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile...
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses Principia to...
Recent Comments